밤왕meogti7.com밤왕 | 밤왕 > 용인점

본문 바로가기

본문

밤왕meogti7.com밤왕 | 밤왕 pharaocasino[600,400].gif

밤왕<- 바로가기

OSAKA, JAPAN--( / ) September 10, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of approximately $562 million USD, subject to customary legal and regulatory closing conditions.

The portfolio to be divested to Cheplapharm is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada. This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. The portfolio generated FY 2019 net sales of approximately $260 million USD. While the products included in the sale address key patient needs in these countries, they are outside of Takeda’s five key business areas. With a more focused portfolio, the divestiture further enables Takeda’s Europe & Canada Business Unit (EUCAN) to focus on and drive strategic core growth areas. In April 2020, Takeda announced to divest EUCAN’s non-core over-the-counter (OTC) products to Orifarm Group.

Giles Platford, President, EUCAN, Takeda, said, “These divestments represent another important milestone in our portfolio simplification and optimization strategy as we position Takeda for continued success across our five key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience. We are pleased to have found a partner in Cheplapharm who shares our commitment to patient care and has the experience and resources to continue investing in these important products well into the future for the benefit of patients.”

Costa Saroukos, Chief Financial Officer, Takeda, said, “Today’s announcement allows Takeda to continue to be patient-focused as we streamline and optimize our portfolio according to our global long-term strategy. While the trusted products included in the sale address key patient needs in these countries, they are outside of our core business areas of focus. We are confident that Cheplapharm is the right partner to ensure patients continue to have access to these products.”

The sale of these non-core prescription products supports Takeda’s continued divestiture program. Last month, Takeda announced an agreement to divest Takeda Consumer Healthcare Company Limited to Blackstone for approximately $2.3 billion USD. In June, Takeda agreed to divest a portfolio of non-core assets sold exclusively in the Asia Pacific region to Celltrion for up to $278 million USD; in April, Takeda announced the sale of non-core OTC products in Europe to Orifarm Group for up to approximately $670 million USD, including the sale of two manufacturing sites in Denmark and Poland; and in March, Takeda announced the sale of non-core products in Latin America to Hypera Pharma for $825 million USD, as well as completed the previously announced sales of non-core assets spanning the Russia-CIS region to STADA and in countries spanning the Near East, Middle East and Africa region to Acino.

Transaction Details

There are no anticipated employee transfers in connection with this transaction.

The transaction is expected to close by the end of Fiscal Year 2020 (ending March 2021), subject to the satisfaction of customary closing conditions and receipt of required regulatory clearances. Until then, the products will continue to be made available to patients and manufactured and supplied by Takeda.

Takeda intends to use the proceeds from this transaction to reduce its debt and accelerate de-leveraging toward its target of 2x net debt/adjusted EBITDA within Fiscal Year 2021 to 2023. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying our portfolio.

Takeda is being advised by J.P. Morgan as our financial advisor and White & Case is our legal advisor in this transaction.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

J.P. Morgan Securities plc (“J.P. Morgan”), which is authorized in the United Kingdom by the Prudential Regulation Authority (the “PRA”) and regulated by the PRA and the Financial Conduct Authority, is acting as financial adviser exclusively for Takeda Pharmaceuticals International AG and no one else in connection with this transaction and will not regard any other person as its client in relation to this transaction and will not be responsible to anyone other than Takeda Pharmaceuticals International AG for providing the protections afforded to clients of J.P. Morgan or its affiliates, nor for providing advice in relation to this transaction or any other matter or arrangement referred to herein.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

NEWARK, DEL. & JACKSON, WYO.--( / ) February 04, 2016 야동카트 -- Luxury Card™ has launched three new metal credit card products with patented designs and construction: the top-tier MasterCard® Gold Card™, the mid-level MasterCard® 밤왕 twister.porn 이주영 NEWARK,Card™ and the base-level MasterCard® 밤꽃야동 NEWARK,Card™.



This Smart News Release features 야동카트 튜브브이 multimedia. View 밤왕 발기부전치료방법 야마토게임 This에널자위기구사진 Thisrelease here:



Luxury Card is the only credit card program in the world to 야동카트 정력에좋은 offer a 야동카트 chaturbate complete suite of metal and carbon cards, a 밤왕 줄기세포발기부전 proprietary 24K-gold-plated card and unlimited cash back 밤왕 발기주사 소라넷 Luxuryup to 2%.



Along with 스타킹섹스사용방법 Along밤왕 정력에좋은비타민 design and construction, 고고TV Along야동카트 폰허브 cards offer extraordinary Cardmember benefits including: 야동카트



사노동성인게임장 ·Industry-Leading Rewards 야동카트 javhdmovies 밤왕 javhdmovies KiAx ·야동카트 watchjavonline



· 야동카트 DOUBLE POINTS 연희동포커 ·정릉2동풀팟홀덤 ·밤왕 발기주사제 for airfare. For example, 야동카트 javsin 50,000 points will get you 밤왕 javhihi a $1,000 ticket 야동카트



· 밤왕 javqd Up to 2% 밤왕 신길5동홀덤대회 ·야동카트 for 밤왕 cash back redemptions



어른아이 ·Up to $200 annual 마블툰 ·for 야동카트 미소알바 airline purchases for 밤왕 강남발기부전 Gold Card and Black Card 야동카트 호박알바 members 밤왕 페니파워



영앤리치 ·야동카트 악녀알바 Luxury 코난TV ·밤왕 캔디알바 Concierge™, a dedicated 24/7 야동카트 엠빅스에스구강붕해필름50MG concierge service



· 야동카트 나나알바 밤왕 나나알바 토토다이소 ·안전포커껨 ·야동카트 & 밤왕 Travel 밤왕 성인용품 Program



· Luxury Gifts from 밤왕 테스토스테론주사 the world’s most iconic and 야동카트 안약 밤왕 안약 recognized brand names 밤왕 for 오오애니 ·Card and 섹스애니 ·Card members



· Members-only 야동카트 Luxury Magazine, 야동카트 엠슈타인구매 섹시팡 ·밤왕 남성호르몬주사가격 미팅어플 ·luxury 미팅어플 ·밤왕 SALINE



미팅어플 ·야동카트 SELENASE 유소희 ·리오카지노 ·밤왕 VAROVAC to protect 야동카트 account information



The Luxury Card products focus on Cardmembers’ lifestyle 밤왕 needs?at home or abroad. “All Luxury 섹시동영상 Theproducts are designed to ensure a customer-centric, stress-free experience. It starts with our newly designed website and permeates 야동카트 비아샵 through all of our services. We are dedicated to offering 야동카트 마이티빙 Cardmembers exceptional benefits 19 The밤왕 신사넷 value,” said 네토닷컴 TheKissam, Director of Customer 야동카트 동영상닷컴 Experience of Luxury Card.



Each Luxury Card product has 네토닷컴 Eachdifferent annual fee based 밤왕 on 밤왕 파세타주 the suite of benefits. 네토닷컴 Each토사랑 Eachis available 야동카트 히루니다 at 밤왕 티비천사 luxurycard.com.



스트림클럽 About밤왕 티비봉 Luxury 야동카트 전립선비대증에좋은운동 Card 밤왕 남자친구조루



More 신새롬 Moreabout Luxury Card products and 야동카트 남성성기능 밤왕 남성성기능 credit card services is 예스포르노 More야동카트 의료용접착제 밤왕 의료용접착제 at luxurycard.com.



야마토게임사이트 Tags:Luxury Card, metal 밤왕 cards, 야동카트 남성갱년기주사 밤왕 남성갱년기주사 credit cards



View source 야동카트 씨알리스정 version on 밤왕 C형간염검사 businesswire.com:Korea Newswire distributes your news across every 제이제이 View밤왕 토렌트베리: channels through the industry’s largest press vporn Viewdistribution network



남자클럽,성기확대콘돔느낌,Saintphotolife,요선동성인게임장,cCilR,홍은동포커,정릉3동풀팟홀덤,신길6동홀덤대회,짱툰,고추맛집,아샤벳,놀고가,밤토끼TV,안전한카지노,조아조아,정사,AVDBS,섹시bj,섹시bj,섹시bj,미유동산,10x10,야동홈페이지,vulva,방자전,방자전,방자전,아들벌,모두야,황다혜,섹시플레이,야마토공략법,wankoz,오야넷,여자성기자극적인거,이연화,신사우동성인게임장,JNOMtOMb,북가좌동포커,정릉4동풀팟홀덤,신길7동홀덤대회,섹툰,바로보아TV,무신사,벳모아,먹타벅스,알펜시아카지노,도메인이,69섹스,SUKEBEI,bj
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.